BUBS AUSTRALIA LIMITED (BUB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BUB - BUBS AUSTRALIA LIMITED

FNArena Sector : Dairy
Year End: June
GICS Industry Group : Food, Beverage & Tobacco
Debt/EBITDA: -0.38
Index:

Bubs is an Australian producer of infant formula and organic baby food and cereals. First listed in 1993, the company relisted in 2017 under the name Bubs Australia.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.12

30 Jan
2025

0.000

OPEN

$0.12

0.000

HIGH

$0.12

1,545,202

LOW

$0.12

TARGET
$0.158 31.9% upside
OTHER COMPANIES IN THE SAME SECTOR
A2M . BFC . BGA . FSF . NUC . NUC . SM1 . TFL .
FNARENA'S MARKET CONSENSUS FORECASTS
BUB: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx - 2.5 - 0.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-2.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx79.7 M
Book Value Per Share xxxxxxxxxxxxxxx4.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-26.3 M
Net Profit Margin xxxxxxxxxxxxxxx-26.33 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-53.44 %
Return on Invested Capital xxxxxxxxxxxxxxx-51.66 %
Return on Assets xxxxxxxxxxxxxxx-31.72 %
Return on Equity xxxxxxxxxxxxxxx-53.44 %
Return on Total Capital xxxxxxxxxxxxxxx-43.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-26.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx6 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx91 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx3.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx0.24 %
Cost of Goods Sold xxxxxxxxxxxxxxx42 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx57 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

23/01/2025

3

Neutral

$0.13

8.33%

On first inspection, Citi is upbeat on Bubs Australia's 2Q25 trading update. All regions generated a positive change in momentum, with higher-than-anticipated margins at the group level of 48% versus the broker's 40% forecast from improved packaging.

Operating cash flow came in at $3.9m, compared to outflows in the previous corresponding period, the analyst states. Management reconfirmed FY25 guidance in revenue and break-even earnings before interest and tax.

Citi is encouraged by the report but remains Neutral, High-risk rated. The analyst is seeking further confirmation of sustainable cash flow and clarity on US FDA approval.

Bell Potter

xx/xx/xxxx

3

xxxxxxxxxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

BUB STOCK CHART